SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Y-mAbs Therapeutics, Inc. – ‘10-K’ for 12/31/22 – ‘EX-101.SCH’

On:  Thursday, 3/30/23, at 4:01pm ET   ·   For:  12/31/22   ·   Accession #:  1558370-23-5073   ·   File #:  1-38650

Previous ‘10-K’:  ‘10-K’ on 3/1/22 for 12/31/21   ·   Next & Latest:  ‘10-K’ on 2/29/24 for 12/31/23   ·   17 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/23  Y-mAbs Therapeutics, Inc.         10-K       12/31/22  106:10M                                    Toppan Merrill Bridge/FA

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.63M 
 2: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     50K 
 3: EX-10.41    Material Contract                                   HTML     39K 
 4: EX-10.42    Material Contract                                   HTML    325K 
 5: EX-21.1     Subsidiaries List                                   HTML     28K 
 6: EX-23       Consent of Expert or Counsel                        HTML     28K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     36K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
10: EX-32.2     Certification -- §906 - SOA'02                      HTML     31K 
16: R1          Document and Entity Information                     HTML     97K 
17: R2          Consolidated Balance Sheets                         HTML    123K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
19: R4          Consolidated Statements of Net Income (Loss) and    HTML     98K 
                Comprehensive Income (Loss)                                      
20: R5          Consolidated Statements of Changes in               HTML     79K 
                Stockholders' Equity                                             
21: R6          Consolidated Statements of Cash Flows               HTML    103K 
22: R7          Organization and Description of Business            HTML     32K 
23: R8          Basis of Presentation                               HTML     36K 
24: R9          Summary of Significant Accounting Policies          HTML    115K 
25: R10         Product Revenue                                     HTML     62K 
26: R11         Net Loss Per Share                                  HTML     42K 
27: R12         Inventories                                         HTML     60K 
28: R13         Intangible Assets, Net                              HTML     32K 
29: R14         Accrued Liabilities                                 HTML     46K 
30: R15         License Agreements and Commitments                  HTML    164K 
31: R16         Stockholders' Equity                                HTML     41K 
32: R17         Share-Based Compensation                            HTML    110K 
33: R18         Related Party Transactions                          HTML     32K 
34: R19         Income Taxes                                        HTML    126K 
35: R20         Other Benefits                                      HTML     31K 
36: R21         Gain From Sale of Priority Review Voucher           HTML     31K 
37: R22         Subsequent Events                                   HTML     32K 
38: R23         Summary of Significant Accounting Policies          HTML    164K 
                (Policies)                                                       
39: R24         Summary of Significant Accounting Policies          HTML     74K 
                (Tables)                                                         
40: R25         Product Revenue (Tables)                            HTML     56K 
41: R26         Net Loss Per Share (Tables)                         HTML     40K 
42: R27         Inventories (Tables)                                HTML     59K 
43: R28         Accrued Liabilities (Tables)                        HTML     46K 
44: R29         License Agreements and Commitments (Tables)         HTML    132K 
45: R30         Share-Based Compensation (Tables)                   HTML    101K 
46: R31         Income Taxes (Tables)                               HTML    129K 
47: R32         BASIS OF PRESENTATION - Accumulated deficit         HTML     32K 
                (Details)                                                        
48: R33         BASIS OF PRESENTATION - Public offering (Details)   HTML     41K 
49: R34         BASIS OF PRESENTATION - Cash and cash equivalents   HTML     31K 
                (Details)                                                        
50: R35         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     36K 
                Concentration of Credit Risk (Details)                           
51: R36         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     30K 
                Inventory (Details)                                              
52: R37         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair   HTML     46K 
                Value Measurement (Details)                                      
53: R38         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     30K 
                Operating Leases (Details)                                       
54: R39         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     30K 
                Revenue Recognition - Product revenue (Details)                  
55: R40         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     65K 
                Revenue Recognition - License revenue (Details)                  
56: R41         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     30K 
                Segment (Details)                                                
57: R42         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     44K 
                Property and Equipment (Details)                                 
58: R43         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     30K 
                Income Taxes (Details)                                           
59: R44         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     31K 
                Research and development (Details)                               
60: R45         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other  HTML     33K 
                policies (Details)                                               
61: R46         PRODUCT REVENUE - Disaggregation (Details)          HTML     41K 
62: R47         PRODUCT REVENUE - Discounts and Allowances          HTML     71K 
                (Details)                                                        
63: R48         PRODUCT REVENUE - Concentrations (Details)          HTML     44K 
64: R49         NET LOSS PER SHARE - Basic and diluted (Details)    HTML     56K 
65: R50         NET LOSS PER SHARE - Anti-dilutive securities       HTML     30K 
                (Details)                                                        
66: R51         Inventories (Details)                               HTML     51K 
67: R52         Intangible Assets, Net (Details)                    HTML     68K 
68: R53         Accrued Liabilities (Details)                       HTML     42K 
69: R54         LICENSE AGREEMENTS AND COMMITMENTS - MSK License    HTML     57K 
                (Details)                                                        
70: R55         LICENSE AGREEMENTS AND COMMITMENTS - LCD33 License  HTML     44K 
                (Details)                                                        
71: R56         LICENSE AGREEMENTS AND COMMITMENTS - MabVax/MSK     HTML     36K 
                License (Details)                                                
72: R57         LICENSE AGREEMENTS AND COMMITMENTS - SADA License   HTML     38K 
                Agreement (Details)                                              
73: R58         LICENSE AGREEMENTS AND COMMITMENTS - Summary of     HTML     69K 
                Significant Agreements and Commitments (Details)                 
74: R59         LICENSE AGREEMENTS AND COMMITMENTS - Other          HTML     47K 
                agreements (Details)                                             
75: R60         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     68K 
                agreements (Details)                                             
76: R61         LICENSE AGREEMENTS AND COMMITMENTS - Lease costs    HTML     37K 
                (Details)                                                        
77: R62         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     46K 
                maturities (Details)                                             
78: R63         LICENSE AGREEMENTS AND COMMITMENTS - Lease term     HTML     33K 
                and discount rate (Details)                                      
79: R64         LICENSE AGREEMENTS AND COMMITMENTS - Severance      HTML     37K 
                Related Benefits (Details)                                       
80: R65         LICENSE AGREEMENTS AND COMMITMENTS - Legal matters  HTML     35K 
                (Details)                                                        
81: R66         STOCKHOLDERS' EQUITY - Authorized, Common and       HTML     47K 
                Preferred Stock (Details)                                        
82: R67         STOCKHOLDERS' EQUITY - Stock grant agreements with  HTML     83K 
                non-employees (Details)                                          
83: R68         STOCKHOLDERS' EQUITY - Issuance of common stock     HTML     42K 
                (Details)                                                        
84: R69         SHARE-BASED COMPENSATION - 2015 Plan (Details)      HTML     37K 
85: R70         SHARE-BASED COMPENSATION - 2018 Plan (Details)      HTML     54K 
86: R71         SHARE-BASED COMPENSATION - Stock-based              HTML     40K 
                compensation expense - Options (Details)                         
87: R72         SHARE-BASED COMPENSATION - Stock Option Valuation   HTML     37K 
                (Details)                                                        
88: R73         SHARE-BASED COMPENSATION - Stock option activity    HTML     67K 
                (Details)                                                        
89: R74         SHARE-BASED COMPENSATION - Stock option grants      HTML     58K 
                (Details)                                                        
90: R75         SHARE-BASED COMPENSATION - Stock option             HTML     35K 
                unrecognized compensation (Details)                              
91: R76         SHARE-BASED COMPENSATION - Restricted Stock Unit    HTML     67K 
                Activity (Details)                                               
92: R77         Related Party Transactions (Details)                HTML     47K 
93: R78         INCOME TAXES - Loss before income taxes (Details)   HTML     44K 
94: R79         INCOME TAXES - Current and deferred income taxes    HTML     45K 
                (Details)                                                        
95: R80         INCOME TAXES - Reconciliation of Income Taxes       HTML     57K 
                (Details)                                                        
96: R81         INCOME TAXES - Deferred assets (Liabilities)        HTML     58K 
                (Details)                                                        
97: R82         INCOME TAXES - Net Operating Loss Carryforwards     HTML     41K 
                (Details)                                                        
98: R83         INCOME TAXES - Unrecognized tax benefits (Details)  HTML     35K 
99: R84         Other Benefits (Details)                            HTML     35K 
100: R85         Gain From Sale of Priority Review Voucher           HTML     40K  
                (Details)                                                        
101: R86         Subsequent Events (Details)                         HTML     39K  
104: XML         IDEA XML File -- Filing Summary                      XML    193K  
102: XML         XBRL Instance -- ymab-20221231x10k_htm               XML   1.92M  
103: EXCEL       IDEA Workbook of Financial Reports                  XLSX    181K  
12: EX-101.CAL  XBRL Calculations -- ymab-20221231_cal               XML    178K 
13: EX-101.DEF  XBRL Definitions -- ymab-20221231_def                XML    793K 
14: EX-101.LAB  XBRL Labels -- ymab-20221231_lab                     XML   1.51M 
15: EX-101.PRE  XBRL Presentations -- ymab-20221231_pre              XML   1.24M 
11: EX-101.SCH  XBRL Schema -- ymab-20221231                         XSD    244K 
105: JSON        XBRL Instance as JSON Data -- MetaLinks              469±   746K  
106: ZIP         XBRL Zipped Folder -- 0001558370-23-005073-xbrl      Zip    974K

‘EX-101.SCH’   —   XBRL Schema — ymab-20221231

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 10.2.0.4 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 3/30/2023 7:21:07 PM -->
<!-- Modified on: 3/30/2023 7:21:07 PM -->
<xsd:schema targetNamespace="http://www.ymabs.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ymab="http://www.ymabs.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
<xsd:annotation>
<xsd:appinfo>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
<link:definition> 99900 - Disclosure - Standard And Custom Axis Domain Defaults </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
<link:definition> 00100 - Statement - Consolidated Balance Sheets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfNetIncomeLossAndComprehensiveIncomeLoss" id="StatementConsolidatedStatementsOfNetIncomeLossAndComprehensiveIncomeLoss">
<link:definition> 00200 - Statement - Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
<link:definition> 00400 - Statement - Consolidated Statements of Cash Flows </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueDiscountsAndAllowancesDetails" id="DisclosureProductRevenueDiscountsAndAllowancesDetails">
<link:definition> 40402 - Disclosure - PRODUCT REVENUE - Discounts and Allowances (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
<link:definition> 40601 - Disclosure - INVENTORIES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventoriesDetailsCalc2" id="DisclosureInventoriesDetailsCalc2">
<link:definition> 40601 - Disclosure - INVENTORIES (Details) Calc 2 </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2" id="DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2">
<link:definition> 40608 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease maturities (Details) (calc 2) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
<link:definition> 40801 - Disclosure - ACCRUED LIABILITIES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails">
<link:definition> 40909 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease maturities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
<link:definition> 41201 - Disclosure - RELATED PARTY TRANSACTIONS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesCurrentAndDeferredIncomeTaxesDetails" id="DisclosureIncomeTaxesCurrentAndDeferredIncomeTaxesDetails">
<link:definition> 41302 - Disclosure - INCOME TAXES - Current and deferred income taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails">
<link:definition> 41303 - Disclosure - INCOME TAXES - Reconciliation of Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesDeferredAssetsLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredAssetsLiabilitiesDetails">
<link:definition> 41304 - Disclosure - INCOME TAXES - Deferred assets (liabilities) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
<link:definition> 00300 - Statement - Consolidated Statements of Changes in Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsTables" id="DisclosureLicenseAgreementsAndCommitmentsTables">
<link:definition> 30903 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
<link:definition> 31103 - Disclosure - SHARE-BASED COMPENSATION (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentationPublicOfferingDetails" id="DisclosureBasisOfPresentationPublicOfferingDetails">
<link:definition> 40202 - Disclosure - BASIS OF PRESENTATION - Public offering (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
<link:definition> 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails">
<link:definition> 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionLicenseRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionLicenseRevenueDetails">
<link:definition> 40306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - License revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
<link:definition> 40308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
<link:definition> 40309 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails">
<link:definition> 40310 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and development (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueDisaggregationDetails" id="DisclosureProductRevenueDisaggregationDetails">
<link:definition> 40401 - Disclosure - PRODUCT REVENUE - Disaggregation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueConcentrationsDetails" id="DisclosureProductRevenueConcentrationsDetails">
<link:definition> 40403 - Disclosure - PRODUCT REVENUE - Concentrations (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
<link:definition> 40502 - Disclosure - NET LOSS PER SHARE - Anti-dilutive securities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIntangibleAssetsNetDetails" id="DisclosureIntangibleAssetsNetDetails">
<link:definition> 40701 - Disclosure - INTANGIBLE ASSETS, NET (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsMskLicenseDetails" id="DisclosureLicenseAgreementsAndCommitmentsMskLicenseDetails">
<link:definition> 40901 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - MSK License (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLcd33LicenseDetails" id="DisclosureLicenseAgreementsAndCommitmentsLcd33LicenseDetails">
<link:definition> 40902 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - LCD33 License (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsMabvaxMskLicenseDetails" id="DisclosureLicenseAgreementsAndCommitmentsMabvaxMskLicenseDetails">
<link:definition> 40903 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - MabVax/MSK License (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsSadaLicenseAgreementDetails" id="DisclosureLicenseAgreementsAndCommitmentsSadaLicenseAgreementDetails">
<link:definition> 40904 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - SADA License Agreement (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsSummaryOfSignificantAgreementsAndCommitmentsDetails" id="DisclosureLicenseAgreementsAndCommitmentsSummaryOfSignificantAgreementsAndCommitmentsDetails">
<link:definition> 40905 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Summary of Significant Agreements and Commitments (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsOtherAgreementsDetails" id="DisclosureLicenseAgreementsAndCommitmentsOtherAgreementsDetails">
<link:definition> 40906 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Other agreements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseAgreementsDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseAgreementsDetails">
<link:definition> 40907 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease agreements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseCostsDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseCostsDetails">
<link:definition> 40908 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease costs (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseTermAndDiscountRateDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseTermAndDiscountRateDetails">
<link:definition> 40910 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease term and discount rate (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsSeveranceRelatedBenefitsDetails" id="DisclosureLicenseAgreementsAndCommitmentsSeveranceRelatedBenefitsDetails">
<link:definition> 40911 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Severance Related Benefits (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLegalMattersDetails" id="DisclosureLicenseAgreementsAndCommitmentsLegalMattersDetails">
<link:definition> 40912 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Legal matters (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquityStockGrantAgreementsWithNonEmployeesDetails" id="DisclosureStockholdersEquityStockGrantAgreementsWithNonEmployeesDetails">
<link:definition> 41002 - Disclosure - STOCKHOLDERS' EQUITY - Stock grant agreements with non-employees (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquityIssuanceOfCommonStockDetails" id="DisclosureStockholdersEquityIssuanceOfCommonStockDetails">
<link:definition> 41003 - Disclosure - STOCKHOLDERS' EQUITY - Issuance of common stock (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensation2015PlanDetails" id="DisclosureShareBasedCompensation2015PlanDetails">
<link:definition> 41101 - Disclosure - SHARE-BASED COMPENSATION - 2015 Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensation2018PlanDetails" id="DisclosureShareBasedCompensation2018PlanDetails">
<link:definition> 41102 - Disclosure - SHARE-BASED COMPENSATION - 2018 Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseOptionsDetails" id="DisclosureShareBasedCompensationStockBasedCompensationExpenseOptionsDetails">
<link:definition> 41103 - Disclosure - SHARE-BASED COMPENSATION - Stock-based compensation expense - Options (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionValuationDetails" id="DisclosureShareBasedCompensationStockOptionValuationDetails">
<link:definition> 41104 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Valuation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
<link:definition> 41105 - Disclosure - SHARE-BASED COMPENSATION - Stock option activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionGrantsDetails" id="DisclosureShareBasedCompensationStockOptionGrantsDetails">
<link:definition> 41106 - Disclosure - SHARE-BASED COMPENSATION - Stock option grants (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionUnrecognizedCompensationDetails" id="DisclosureShareBasedCompensationStockOptionUnrecognizedCompensationDetails">
<link:definition> 41107 - Disclosure - SHARE-BASED COMPENSATION - Stock option unrecognized compensation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationRestrictedStockUnitActivityDetails" id="DisclosureShareBasedCompensationRestrictedStockUnitActivityDetails">
<link:definition> 41108 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Unit Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails">
<link:definition> 41305 - Disclosure - INCOME TAXES - Net Operating Loss Carryforwards (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureOtherBenefitsDetails" id="DisclosureOtherBenefitsDetails">
<link:definition> 41401 - Disclosure - OTHER BENEFITS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureGainFromSaleOfPriorityReviewVoucherDetails" id="DisclosureGainFromSaleOfPriorityReviewVoucherDetails">
<link:definition> 41501 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
<link:definition> 41601 - Disclosure - SUBSEQUENT EVENTS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition> 00090 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
<link:definition> 00105 - Statement - Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
<link:definition> 10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
<link:definition> 10201 - Disclosure - BASIS OF PRESENTATION </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
<link:definition> 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenue" id="DisclosureProductRevenue">
<link:definition> 10401 - Disclosure - PRODUCT REVENUE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
<link:definition> 10501 - Disclosure - NET LOSS PER SHARE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventories" id="DisclosureInventories">
<link:definition> 10601 - Disclosure - INVENTORIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIntangibleAssetsNet" id="DisclosureIntangibleAssetsNet">
<link:definition> 10701 - Disclosure - INTANGIBLE ASSETS, NET </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
<link:definition> 10801 - Disclosure - ACCRUED LIABILITIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitments" id="DisclosureLicenseAgreementsAndCommitments">
<link:definition> 10901 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
<link:definition> 11001 - Disclosure - STOCKHOLDERS' EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
<link:definition> 11101 - Disclosure - SHARE-BASED COMPENSATION </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
<link:definition> 11201 - Disclosure - RELATED PARTY TRANSACTIONS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
<link:definition> 11301 - Disclosure - INCOME TAXES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureOtherBenefits" id="DisclosureOtherBenefits">
<link:definition> 11401 - Disclosure - OTHER BENEFITS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureGainFromSaleOfPriorityReviewVoucher" id="DisclosureGainFromSaleOfPriorityReviewVoucher">
<link:definition> 11501 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
<link:definition> 11601 - Disclosure - SUBSEQUENT EVENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition> 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
<link:definition> 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueTables" id="DisclosureProductRevenueTables">
<link:definition> 30403 - Disclosure - PRODUCT REVENUE (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
<link:definition> 30503 - Disclosure - NET LOSS PER SHARE (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
<link:definition> 30603 - Disclosure - INVENTORIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
<link:definition> 30803 - Disclosure - ACCRUED LIABILITIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
<link:definition> 31303 - Disclosure - INCOME TAXES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentationAccumulatedDeficitDetails" id="DisclosureBasisOfPresentationAccumulatedDeficitDetails">
<link:definition> 40201 - Disclosure - BASIS OF PRESENTATION - Accumulated deficit (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentationCashAndCashEquivalentsDetails" id="DisclosureBasisOfPresentationCashAndCashEquivalentsDetails">
<link:definition> 40203 - Disclosure - BASIS OF PRESENTATION - Cash and cash equivalents (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails">
<link:definition> 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventory (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOperatingLeasesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesOperatingLeasesDetails">
<link:definition> 40304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Operating Leases (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionProductRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionProductRevenueDetails">
<link:definition> 40305 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Product revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails">
<link:definition> 40307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesOtherPoliciesDetails">
<link:definition> 40311 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other policies (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails" id="DisclosureNetLossPerShareBasicAndDilutedDetails">
<link:definition> 40501 - Disclosure - NET LOSS PER SHARE - Basic and diluted (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquityAuthorizedCommonAndPreferredStockDetails" id="DisclosureStockholdersEquityAuthorizedCommonAndPreferredStockDetails">
<link:definition> 41001 - Disclosure - STOCKHOLDERS' EQUITY - Authorized, Common and Preferred Stock (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails">
<link:definition> 41301 - Disclosure - INCOME TAXES - Loss before income taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails">
<link:definition> 41306 - Disclosure - INCOME TAXES - Unrecognized tax benefits (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20221231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</xsd:appinfo>
</xsd:annotation>
<xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
<xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
<xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
<xsd:element name="IncreaseDecreaseInAccruedLiabilitiesAndOther" id="ymab_IncreaseDecreaseInAccruedLiabilitiesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element name="NumberOfLicenseAgreements" id="ymab_NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
<xsd:element id="ymab_Cd33LicenseAgreementMember" name="Cd33LicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="SponsoredResearchAgreementMember" id="ymab_SponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="MasterDataServicesAgreementMember" id="ymab_MasterDataServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_CoreFacilityServiceAgreementMember" name="CoreFacilityServiceAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeasePayablePerMonth" name="LeasePayablePerMonth" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="OrganizationAndDescriptionOfBusinessAbstract" id="ymab_OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="BasisOfPresentationAbstract" id="ymab_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="PatentCostsPolicyTextBlock" id="ymab_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="AccruedClinicalCostsCurrent" id="ymab_AccruedClinicalCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element name="AccruedCompensationAndBoardFeesCurrent" id="ymab_AccruedCompensationAndBoardFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element name="TotalSharesAuthorized" id="ymab_TotalSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
<xsd:element name="NumberOfVotesPerCommonStock" id="ymab_NumberOfVotesPerCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="OtherBenefitsDisclosureAbstract" id="ymab_OtherBenefitsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="OtherBenefitsDisclosureTextBlock" id="ymab_OtherBenefitsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="DeferredTaxAssetsAccruedRoyalty" id="ymab_DeferredTaxAssetsAccruedRoyalty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant"/>
<xsd:element name="EquityIncentivePlan2015Member" id="ymab_EquityIncentivePlan2015Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" id="ymab_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeaseArrangementCorporateHeadquartersNewYorkMember" name="LeaseArrangementCorporateHeadquartersNewYorkMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeaseArrangementOfficeSpaceDenmarkMember" name="LeaseArrangementOfficeSpaceDenmarkMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="ShareholderMskMember" id="ymab_ShareholderMskMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="FixedRentPayablePerAnnum" id="ymab_FixedRentPayablePerAnnum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="ymab_LicenseAndOtherAgreementsMember" name="LicenseAndOtherAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="OwnershipVotingPower" id="ymab_OwnershipVotingPower" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
<xsd:element name="OptionPriceAsPercentageOfFairMarketValueOfCommonStockOnGrantDate" id="ymab_OptionPriceAsPercentageOfFairMarketValueOfCommonStockOnGrantDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="EquityIncentivePlan2018Member" id="ymab_EquityIncentivePlan2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="GranteeOwningMoreThanTenPercentOfVotingPowerMember" id="ymab_GranteeOwningMoreThanTenPercentOfVotingPowerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_DeferredTaxAssetsNetOfLiabilitiesGross" name="DeferredTaxAssetsNetOfLiabilitiesGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element name="AccruedManufacturingCostsCurrent" id="ymab_AccruedManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="ymab_LeaseArrangementLaboratoryNewJerseyMember" name="LeaseArrangementLaboratoryNewJerseyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ResearchersEmployeesOfMskMember" name="ResearchersEmployeesOfMskMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_NumberOfIndividuals" name="NumberOfIndividuals" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_LicenseAgreementsAndCommitmentsAbstract" name="LicenseAgreementsAndCommitmentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeClinicalMilestonePaymentsDue" name="ArrangementOtherThanCollaborativeClinicalMilestonePaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeRegulatoryMilestonePaymentsDue" name="ArrangementOtherThanCollaborativeRegulatoryMilestonePaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeSalesBasedMilestonePaymentsDue" name="ArrangementOtherThanCollaborativeSalesBasedMilestonePaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeAnnualMinimumRoyaltiesPayable" name="ArrangementOtherThanCollaborativeAnnualMinimumRoyaltiesPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeAnnualMinimumRoyaltiesPayableFromTenthAnniversary" name="ArrangementOtherThanCollaborativeAnnualMinimumRoyaltiesPayableFromTenthAnniversary" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeResearchServicePeriod" name="ArrangementOtherThanCollaborativeResearchServicePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeNumberOfServiceAgreements" name="ArrangementOtherThanCollaborativeNumberOfServiceAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_GrossProceedsFromIssuanceOfShares" name="GrossProceedsFromIssuanceOfShares" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_DeferredTaxAssetLeaseLiability" name="DeferredTaxAssetLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="ymab_OperatingLossCarryforwardsWithExpirationDates" name="OperatingLossCarryforwardsWithExpirationDates" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="ymab_OperatingLossCarryforwardsIndefinite" name="OperatingLossCarryforwardsIndefinite" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_SadaLicenseAgreementMember" name="SadaLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeAdditionalSalesBasedMilestonePaymentsDueOtherConstructs" name="ArrangementOtherThanCollaborativeAdditionalSalesBasedMilestonePaymentsDueOtherConstructs" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_CompensationExpenseHealthInsuranceBenefits" name="CompensationExpenseHealthInsuranceBenefits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_NotesReceivableTerm" name="NotesReceivableTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_NotesReceivableInterestRate" name="NotesReceivableInterestRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_NumberOfEmployeesAcquired" name="NumberOfEmployeesAcquired" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_OtherAgreementsMember" name="OtherAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_MskMember" name="MskMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeaseArrangementManufacturingFacilityIndianaMember" name="LeaseArrangementManufacturingFacilityIndianaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LesseeOperatingLeaseMonthlyAccessFee" name="LesseeOperatingLeaseMonthlyAccessFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent" name="AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeCashPayments" name="ArrangementOtherThanCollaborativeCashPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_MilestonesAbstract" name="MilestonesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_FinancialStatementInformationAbstract" name="FinancialStatementInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LesseeOperatingLeaseInitialFeeAndAccessFee" name="LesseeOperatingLeaseInitialFeeAndAccessFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_CostsIncurredAsResultOfGlobalIntangibleLowTaxedIncome" name="CostsIncurredAsResultOfGlobalIntangibleLowTaxedIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeClinicalMilestonePaymentsDueNotProbable" name="ArrangementOtherThanCollaborativeClinicalMilestonePaymentsDueNotProbable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_PublicOfferingFebruary2021Member" name="PublicOfferingFebruary2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_PublicOfferingFebruary2021UnderwritersOptionMember" name="PublicOfferingFebruary2021UnderwritersOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_DevelopmentAndCommercializationArrangementMember" name="DevelopmentAndCommercializationArrangementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ScicloneInternationalPharmaceuticalsLtdMember" name="ScicloneInternationalPharmaceuticalsLtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_NumberOfCustomers" name="NumberOfCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="ymab_MckessonMember" name="MckessonMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_CardinalHealthMember" name="CardinalHealthMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_AccruedSalesReservesCurrent" name="AccruedSalesReservesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ProductDanyelzaMember" name="ProductDanyelzaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_AdiumPharmaS.aMember" name="AdiumPharmaS.aMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ReserveForDiscountsAndAllowancesTableTextBlock" name="ReserveForDiscountsAndAllowancesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsRemainingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsRemainingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="ymab_ReservesForDiscountsAndAllowancesRollForward" name="ReservesForDiscountsAndAllowancesRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ReserveForDiscountsBalance" name="ReserveForDiscountsBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ReserveForDiscountsAdditions" name="ReserveForDiscountsAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_ReserveForDiscountsReduction" name="ReserveForDiscountsReduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_SalesReturnLiabilityBalance" name="SalesReturnLiabilityBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_SalesReturnLiabilityAdditions" name="SalesReturnLiabilityAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_SalesReturnLiabilityReduction" name="SalesReturnLiabilityReduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_ReservesAndAllowancesBalance" name="ReservesAndAllowancesBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ReservesAndAllowancesAdditions" name="ReservesAndAllowancesAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_ReservesAndAllowancesReductions" name="ReservesAndAllowancesReductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_FinancialStatementAccruedLiabilitiesMember" name="FinancialStatementAccruedLiabilitiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_FinancialStatementAccountsReceivableMember" name="FinancialStatementAccountsReceivableMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold" id="ymab_RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ThreeCustomersMember" id="ymab_ThreeCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateLiabilityBalance" id="ymab_ContractualAllowanceAndGovernmentRebateLiabilityBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateLiabilityAdditions" id="ymab_ContractualAllowanceAndGovernmentRebateLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateLiabilityReduction" id="ymab_ContractualAllowanceAndGovernmentRebateLiabilityReduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ArrangementOtherThanCollaborativeTimeBasedMilestoneAccrualPeriod" id="ymab_ArrangementOtherThanCollaborativeTimeBasedMilestoneAccrualPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="TakedaIsraelMember" id="ymab_TakedaIsraelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="LicenseAndDistributionArrangementMember" id="ymab_LicenseAndDistributionArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="DistributionArrangementMember" id="ymab_DistributionArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodPercent" id="ymab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="IntangibleAssetsCostsIncurredButNotYetPaid" id="ymab_IntangibleAssetsCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="IntangibleAssetsDisclosureAbstract" id="ymab_IntangibleAssetsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" id="ymab_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="RevenueAbstract" id="ymab_RevenueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="PaymentTermsDiscountForPromptPaymentPercent" id="ymab_PaymentTermsDiscountForPromptPaymentPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="AsdMember" id="ymab_AsdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="InventoryCurrentAndNoncurrentTable" id="ymab_InventoryCurrentAndNoncurrentTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="InventoryCurrentAndNoncurrentLineItems" id="ymab_InventoryCurrentAndNoncurrentLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" id="ymab_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="InventoryCurrentAndNoncurrent" id="ymab_InventoryCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="CurrentAssetsMember" id="ymab_CurrentAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="NoncurrentAssetsMember" id="ymab_NoncurrentAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="AccruedLiabilitiesRelatedPartiesCurrent" id="ymab_AccruedLiabilitiesRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="AreaOfRealEstatePropertyAdditionalArea" id="ymab_AreaOfRealEstatePropertyAdditionalArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="CompensationExpenseEmploymentAgreementSalariesAndCertainBenefitsContinuation" id="ymab_CompensationExpenseEmploymentAgreementSalariesAndCertainBenefitsContinuation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="CompensationExpenseEmploymentAndEquityAwardAgreementSalariesAndCertainBenefitsContinuationAndShareBasedCompensation" id="ymab_CompensationExpenseEmploymentAndEquityAwardAgreementSalariesAndCertainBenefitsContinuationAndShareBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="FairValueAssetsLevel1ToLevel2TransfersAmount1" id="ymab_FairValueAssetsLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="FairValueAssetsLevel2ToLevel1TransfersAmount1" id="ymab_FairValueAssetsLevel2ToLevel1TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ScheduleOfCompensationArrangementWithIndividualTable" id="ymab_ScheduleOfCompensationArrangementWithIndividualTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="CompensationArrangementWithIndividualLineItems" id="ymab_CompensationArrangementWithIndividualLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ChiefExecutiveOfficerFormerMember" id="ymab_ChiefExecutiveOfficerFormerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ArrangementOtherThanCollaborativeTimeBasedMilestonePaymentsDueAccruedLiabilities" id="ymab_ArrangementOtherThanCollaborativeTimeBasedMilestonePaymentsDueAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="LicenseTransferMember" id="ymab_LicenseTransferMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="LicenseMilestoneMember" id="ymab_LicenseMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="IndividualsUnderRetentionProgramMember" id="ymab_IndividualsUnderRetentionProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="IndividualsNotUnderRetentionProgramMember" id="ymab_IndividualsNotUnderRetentionProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="DeferredCompensationArrangementCashBonusValue" id="ymab_DeferredCompensationArrangementCashBonusValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="AccruedMilestonePaymentsNoncurrent" id="ymab_AccruedMilestonePaymentsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="AcquisitionOfTreasurySharesUponRepaymentOfSecuredPromissoryNote" id="ymab_AcquisitionOfTreasurySharesUponRepaymentOfSecuredPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ReservesForDiscountsAndAllowancesChangeInEstimate" id="ymab_ReservesForDiscountsAndAllowancesChangeInEstimate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateChangeInEstimate" id="ymab_ContractualAllowanceAndGovernmentRebateChangeInEstimate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="NumberOfIndividualsRepaymentOfNote" id="ymab_NumberOfIndividualsRepaymentOfNote" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="LawsuitFiledByShareholderU.s.DistrictCourtSouthernDistrictOfNewYorkAugust252021Member" id="ymab_LawsuitFiledByShareholderU.s.DistrictCourtSouthernDistrictOfNewYorkAugust252021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="NumberOfStockholdersThatFiledLawsuit" id="ymab_NumberOfStockholdersThatFiledLawsuit" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="ArrangementOtherThanCollaborativeRegulatoryMilestonePaymentsReceivable" id="ymab_ArrangementOtherThanCollaborativeRegulatoryMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ArrangementOtherThanCollaborativeSalesBasedMilestonePaymentsReceivable" id="ymab_ArrangementOtherThanCollaborativeSalesBasedMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="AssetImpairmentChargesNoteReceivable" id="ymab_AssetImpairmentChargesNoteReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ForeignCurrencyTransactionGainLossBeforeTaxAndOtherTransactions" id="ymab_ForeignCurrencyTransactionGainLossBeforeTaxAndOtherTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" id="ymab_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" id="ymab_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="LicenseAgreementAndOtherAgreementsCapitalizedIntangibleAssetMember" id="ymab_LicenseAgreementAndOtherAgreementsCapitalizedIntangibleAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="StrategicRestructuringPlan2023Member" id="ymab_StrategicRestructuringPlan2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="AccelerationOfStockBasedCompensationMember" id="ymab_AccelerationOfStockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="RestructuringAndRelatedCostRestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" id="ymab_RestructuringAndRelatedCostRestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="PriorityReviewVoucherFirstSaleIncomePercentageCounterparty" id="ymab_PriorityReviewVoucherFirstSaleIncomePercentageCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="PriorityReviewVoucherSubsequentSaleIncomePercentageCounterparty" id="ymab_PriorityReviewVoucherSubsequentSaleIncomePercentageCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="PriorityReviewVoucherSaleIncomePercentageRetained" id="ymab_PriorityReviewVoucherSaleIncomePercentageRetained" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="PriorityReviewVoucherSaleIncomePercentageCounterparty" id="ymab_PriorityReviewVoucherSaleIncomePercentageCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="AssetSaleConsiderationReceived" id="ymab_AssetSaleConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="LicenseAgreementTermMinimum" id="ymab_LicenseAgreementTermMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
<xsd:element name="ArrangementOtherThanCollaborativeAnnualMinimumRoyaltiesPayablePatentIssued" id="ymab_ArrangementOtherThanCollaborativeAnnualMinimumRoyaltiesPayablePatentIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="PriorityReviewVoucherSaleIncomePercentageDueToCounterparty" id="ymab_PriorityReviewVoucherSaleIncomePercentageDueToCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="ArrangementOtherThanCollaborativeDevelopmentMilestonePaymentsDue" id="ymab_ArrangementOtherThanCollaborativeDevelopmentMilestonePaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="LawsuitFiledByShareholderInCourtOfChanceryOfStateOfDelawareFebruary82023Member" id="ymab_LawsuitFiledByShareholderInCourtOfChanceryOfStateOfDelawareFebruary82023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="DeferredTaxAssetsCapitalizedResearchAndExperimentation" id="ymab_DeferredTaxAssetsCapitalizedResearchAndExperimentation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="EffectiveIncomeTaxRateReconciliationDeferredAdjustmentsAmount" id="ymab_EffectiveIncomeTaxRateReconciliationDeferredAdjustmentsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="LicenseAgreementMember" id="ymab_LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="MskAndMabvaxMember" id="ymab_MskAndMabvaxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="MskAndMitMember" id="ymab_MskAndMitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
</xsd:schema>

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Y-mAbs Therapeutics, Inc.         10-K       12/31/23  101:10M                                    Toppan Merrill Bridge/FA
 5/08/23  Y-mAbs Therapeutics, Inc.         10-Q        3/31/23   85:7.4M                                   Toppan Merrill Bridge/FA
 3/30/23  Y-mAbs Therapeutics, Inc.         S-8         3/30/23    4:168K                                   Toppan Merrill Bridge/FA
 3/30/23  Y-mAbs Therapeutics, Inc.         S-3                    5:975K                                   Toppan Merrill Bridge/FA

13 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/07/22  Y-mAbs Therapeutics, Inc.         10-Q        9/30/22   88:8.4M                                   Toppan Merrill Bridge/FA
 8/08/22  Y-mAbs Therapeutics, Inc.         10-Q        6/30/22   85:8M                                     Toppan Merrill Bridge/FA
 5/09/22  Y-mAbs Therapeutics, Inc.         10-Q        3/31/22   85:7.2M                                   Toppan Merrill Bridge/FA
 5/06/21  Y-mAbs Therapeutics, Inc.         10-Q        3/31/21   76:6.3M                                   Toppan Merrill Bridge/FA
 2/19/21  Y-mAbs Therapeutics, Inc.         8-K:7,8,9   2/17/21   15:2.7M                                   Toppan Merrill/FA
12/22/20  Y-mAbs Therapeutics, Inc.         8-K:1,9    12/17/20   11:674K                                   Toppan Merrill/FA
11/05/20  Y-mAbs Therapeutics, Inc.         10-Q        9/30/20   68:6.7M                                   Toppan Merrill Bridge/FA
10/08/20  Y-mAbs Therapeutics, Inc.         8-K:1,9    10/07/20   11:294K                                   Toppan Merrill/FA
 4/21/20  Y-mAbs Therapeutics, Inc.         8-K:1,9     4/15/20    2:348K                                   Toppan Merrill/FA
12/19/19  Y-mAbs Therapeutics, Inc.         8-K:1,9    12/13/19    3:170K                                   Toppan Merrill/FA
 9/19/19  Y-mAbs Therapeutics, Inc.         8-K:1,9     9/13/19    2:129K                                   Toppan Merrill/FA
 9/07/18  Y-mAbs Therapeutics, Inc.         S-1/A                  5:4.4M                                   Toppan Merrill-FA
 8/24/18  Y-mAbs Therapeutics, Inc.         S-1                   31:12M                                    Toppan Merrill-FA
↑Top
Filing Submission 0001558370-23-005073   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., May 12, 11:08:09.2am ET